NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 976.2 DKK | +1.06% |
|
+0.90% | +39.84% |
| 07:46am | Novo Nordisk: FDA applications for icodec | CF |
| 06:32am | Novo Nordisk Receives Additional Information Request from US FDA for Insulin Icodec | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
976.2
DKK
Average target price
953.5
DKK
Spread / Average Target
-2.32%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +39.84% | 628B | |
| +61.22% | 846B | |
| -4.66% | 360B | |
| +16.77% | 322B | |
| +8.50% | 297B | |
| +13.94% | 240B | |
| +15.82% | 223B | |
| +1.84% | 224B | |
| +11.68% | 173B | |
| -1.53% | 161B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Novo Nordisk Signs MoU with Indonesia's Bio Farma for Insulin Packaging
